Ownership and insider activity for PMGC Holdings Inc. (ELAB): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists.
Price
| Price | $4.77 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-01 | Parry Jeffrey | A-Award | 75,046 | $133K |
| 2026-06-01 | Kovalyov George | A-Award | 75,046 | $133K |
| 2026-06-01 | Daley Juliana | A-Award | 75,046 | $133K |
| 2026-06-01 | Braeden Lichti | A-Award | 450,277 | $797K |
| 2023-11-13 | Parry Jeffrey | |||
| 2022-09-30 | Parry Jeffrey | 1 | $26K | |
| 2022-09-30 | Parry Jeffrey | 4 | $392K | |
| 2023-11-13 | Daley Juliana | |||
| 2023-06-01 | Daley Juliana | 4 | $392K | |
| 2024-03-06 | Kovalyov George |
Balance Sheet (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $13351 | $411858 | $1.2M | $3.3M | $4.0M | $5.4M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $371 | $1710 | $12854 | $36161 | $5276 | $340531 |
| Inventory | 0 | $160817 | $230145 | $495667 | $1044 | $95098 |
| Total Current Assets | $17022 | $636525 | $1.6M | $4.9M | $6.1M | $6.9M |
| Property, Plant & Equipment | 0 | $29725 | $330088 | $1741 | $1087 | $2.1M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | $977774 |
| Intangible Assets | 0 | 0 | 0 | 0 | $2.8M | $2.9M |
| Total Assets | $17022 | $666250 | $1.9M | $5.2M | $9.0M | $12.9M |
| Accounts Payable | $154 | $98175 | $210840 | $596147 | $481000 | $697633 |
| Short-term Debt | $24000 | 0 | 0 | 0 | 0 | $1.3M |
| Total Current Liabilities | $40611 | $215622 | $588272 | $1.3M | $1.8M | $3.9M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | $1.1M |
| Total Liabilities | $40611 | $215622 | $760873 | $1.4M | $2.3M | $5.0M |
| Retained Earnings | -$137366 | -$922105 | -$2.7M | -$7.0M | -$13.3M | -$21.0M |
| Total Equity | -$23589 | $450628 | $1.1M | $3.8M | $6.7M | $7.8M |
| Total Debt | $24000 | 0 | $283217 | $210489 | 0 | $2.6M |
| Net Debt | $10649 | -$411858 | -$871684 | -$3.1M | -$4.0M | -$2.8M |
| Working Capital | -$23589 | $420903 | $963050 | $3.6M | $4.3M | $2.9M |
Financial Health
| Debt / Equity | 0.83 |
| Current Ratio | 1.36 |
Profitability
| Return on Equity | -98.35% |
| Return on Invested Capital | -70.17% |
| Return on Assets | -59.90% |
| Gross Margin | 10.31% |
| Operating Margin | -477.02% |
| Net Margin | -522.97% |
Related companies: ATXI · BCTXZ · DRMA · MLEC · NCEL · NKGN · PBM
Explore sector: Healthcare · Biotechnology
More sections of ELAB: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks